Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Apogee Therapeutics, Inc.

Market Cap 6.77B 5.91B 5.46B 5.12B 9.59B 639B 9.66B 64.85B 25.13B 315B 25.42B 24.88B 1,092B P/E 2026 *
-20.8x
P/E 2027 * -16.4x
Enterprise Value 5.82B 5.07B 4.69B 4.4B 8.23B 549B 8.3B 55.71B 21.59B 270B 21.84B 21.37B 938B EV / Sales 2026 *
698x
EV / Sales 2027 * 525x
Free-Float
71.72%
Yield 2026 *
-
Yield 2027 * -
1 day+2.21%
1 week+2.32%
Current month+10.03%
1 month+15.47%
3 months+31.94%
6 months+15.08%
Current year+19.74%
1 week 84.01
Extreme 84.01
91.03
1 month 75
Extreme 75
91.9
Current year 60.35
Extreme 60.35
95.32
1 year 34.34
Extreme 34.34
95.32
3 years 14.19
Extreme 14.19
95.32
5 years 14.19
Extreme 14.19
95.32
10 years 14.19
Extreme 14.19
95.32
Manager TitleAgeSince
Chief Executive Officer 36 2022-08-31
Director of Finance/CFO 60 2022-12-31
Chief Tech/Sci/R&D Officer - 2023-04-30
Director TitleAgeSince
Director/Board Member 62 2023-05-31
Director/Board Member 48 2023-05-31
Director/Board Member 54 2023-06-21
Date Insider Type Main position Quantity % Market Cap.
06-09Sell

Chief Executive Officer

-20,000 0.0357%
06-08Free

Director

7,657 0.0137%
06-08Free

Founder

7,657 0.0137%
Change 5-day change 1-year change 3-year change Capi.($)
+2.21%+2.32%+119.48% - 6.77B
+1.44%+1.71%-10.63%-9.16% 43.13B
+3.31%+5.93%+308.19%+562.02% 34.65B
+2.84%+2.14%+6.87%+34.93% 30.03B
-1.70%-7.54%+8.51%-22.34% 28B
-1.90%-1.56%+11.62%+19.80% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+52.04%+107.47% 13.14B
-0.57%-2.43%+5.18%+4.20% 12.53B
-0.26%+1.15%+100.27%+80.69% 12.25B
Average +0.59%+0.76%+66.84%+97.20% 21.93B
Weighted average by Cap. +0.82%+1.26%+67.02%+113.23%

Financials

2026 *2027 *
Net sales 8.33M 7.27M 6.72M 6.3M 11.79M 786M 11.89M 79.78M 30.91M 387M 31.28M 30.61M 1.34B 11.54M 10.06M 9.3M 8.72M 16.33M 1.09B 16.46M 110M 42.81M 536M 43.31M 42.38M 1.86B
Net income -319M -278M -257M -241M -451M -30.06B -455M -3.05B -1.18B -14.8B -1.2B -1.17B -51.4B -409M -357M -330M -309M -580M -38.62B -584M -3.92B -1.52B -19.01B -1.54B -1.5B -66.04B
Net Debt -955M -833M -770M -722M -1.35B -90.07B -1.36B -9.14B -3.54B -44.34B -3.58B -3.51B -154B -711M -620M -574M -538M -1.01B -67.08B -1.01B -6.81B -2.64B -33.02B -2.67B -2.61B -115B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
26-06-18 90.38 $ +2.21% 1,970,054
26-06-17 88.43 $ +3.74% 1,223,821
26-06-16 85.24 $ -1.10% 1,045,104
26-06-15 86.19 $ -2.42% 709,327
26-06-12 88.33 $ -1.31% 1,302,759
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
90.38USD
Average target price
119.50USD
Spread / Average Target
+32.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!